INTABIOTECH

CrociVance™

STANDARDIZED SAFFRON EXTRACT

Saffron Beyond the Spice

From *Crocus sativus* phytochemistry to evidence-based human health applications

MOOD	SLEEP	RESILIENCE
Best-developed human evidence	Promising RCT + meta-analytic evidence	Mechanistically coherent positioning

Scientific Review & Ingredient Innovation Perspective

September 2026 | INTABIOTECH

José M. López, BSc, MD, PhD, LLD (c)

PRECISION SAFFRON SCIENCE

EXECUTIVE SCIENTIFIC POSITIONING

Where the evidence is strongest — and where restraint matters

Saffron has progressed from a high-value culinary spice to a serious subject of nutritional neuroscience. The most credible commercial opportunity is not to portray it as a universal botanical, but to build around the specific domains where controlled human studies are most coherent: mood, psychological stress and sleep. Cognitive, cardiometabolic, ocular, reproductive and sexual-health findings remain scientifically relevant, but they do not currently carry the same evidential weight.

DOMAIN	EVIDENCE SIGNAL	CROCiVANCE™ ROLE
Mood / depressive & anxiety symptoms	Moderate; multiple RCTs + 2026 GRADE meta-analysis	Primary evidence pillar
Sleep quality	Promising; several RCTs + meta-analysis	Primary / adjacent pillar
Cognition / healthy ageing	Promising but insufficient for clinical recommendation	Research & future substantiation

CORE SCIENTIFIC BOUNDARY

Published trials performed with third-party proprietary saffron extracts are ingredient-class evidence. They must not be represented as CrociVance™-specific efficacy data unless analytical bridging or direct product-specific clinical substantiation has been established.

PRODUCT-DEVELOPMENT PRINCIPLE

Do not assign a convenient crocin percentage or a “clinically equivalent” daily dose before the final CrociVance™ CoA, extraction process, chromatographic fingerprint and stability profile are fixed.

CONTENTS

BACKGROUND

01 Saffron as a modern evidence-based botanical

Saffron, the dried stigmas of Crocus sativus L., occupies an unusual position at the interface between food, traditional use and modern nutraceutical science. Its high commercial value historically reflected the extraordinary labour involved in harvesting and processing the stigmas. Its contemporary scientific value derives from a distinctive phytochemical architecture dominated by apocarotenoids and volatile compounds that can be analytically characterised and increasingly linked to human clinical outcomes.

The strongest proposition is not that saffron is a universal therapeutic agent. Rather, appropriately characterised saffron preparations appear capable of modulating several biological systems relevant to mood, psychological stress, sleep and neurocognitive function, with additional — but less mature — evidence in cardiometabolic, ocular, reproductive and sexual-health domains.

A 2026 GRADE-assessed systematic review and meta-analysis of 34 randomised controlled trials involving 1,769 participants reported significant reductions in self-reported depression and anxiety scales after saffron supplementation. The same analysis did not show consistent effects across clinician-rated scales, and the overall certainty of evidence was moderate rather than definitive. [1]

INTERPRETATION

The discrepancy between self-reported and clinician-rated outcomes is scientifically important. It supports a credible mood-related signal, but argues against presenting saffron as a nutraceutical equivalent of psychiatric treatment.

COMPOSITION

02 Phytochemistry and standardisation

Modern saffron science centres on four groups of constituents: crocins, crocetin, picrocrocin and safranal. Crocins are water-soluble glycosylated apocarotenoids responsible for much of saffron's characteristic colour. Crocetin is their aglycone and becomes particularly relevant when oral pharmacokinetics are considered. Picrocrocin contributes bitterness, whereas safranal is a key volatile associated with saffron aroma and has attracted significant neuropharmacological interest. [6,7]

The expression "saffron extract" is therefore scientifically insufficient by itself. Two preparations may share the same botanical source while differing materially in plant-part selection, extraction solvent, drug-to-extract ratio, crocin profile, safranal concentration, drying technology, carrier system, storage stability and resulting systemic exposure.

The clinically appropriate question is not simply whether saffron works. It is: which chemically characterised preparation, at which dose, in which population and against which pre-specified outcome?

BIOLOGICAL TRANSLATION: FROM RAW MATERIAL TO SYSTEMIC EXPOSURE

CROCINS	DIGESTION	CROCETIN	TARGET TISSUES
Extract fingerprint	Hydrolysis / conversion	Systemic metabolite	Potential biological activity

CLINICAL EVIDENCE

03 Mood and emotional wellbeing

Among proposed saffron applications, psychological and affective health currently has the most substantial randomised human evidence. The 2026 meta-analysis reported statistically significant effects on the Beck Depression Inventory and Beck Anxiety Inventory, while Hamilton-rated depression and anxiety outcomes and Profile of Mood States did not show the same pooled benefit. Heterogeneity was high for several analyses. [1]

A particularly informative 2025 randomised, double-blind, placebo-controlled trial enrolled 202 adults aged 18–70 years with subclinical depressive symptoms. Participants received a standardised saffron extract at 28 mg/day or placebo for 12 weeks. The saffron group showed a significantly greater improvement in DASS-21 depression score, with a between-group effect size of approximately d = 0.39; a clinically significant score reduction occurred in

72.3% of saffron-treated participants versus 54.3% receiving placebo. Several secondary outcomes did not differ significantly, and the placebo response was substantial. [2]

Those limitations should be retained in any serious scientific communication. They make the evidence more credible: biological interventions rarely improve every endpoint simultaneously. The correct positioning is that saffron has a clinically relevant and increasingly reproducible signal in mood-related outcomes, not that it has been established as a treatment for depressive disorders.

COMMERCIAL IMPLICATION

CrociVance™ can legitimately be developed around the mood–stress domain as an evidence-led botanical platform, while keeping therapeutic language separate from food-supplement communication and from product-specific substantiation.

BIOLOGICAL RATIONALE

04 Mechanistic plausibility

Several mechanisms have been proposed to explain saffron's neuropsychological effects. Experimental literature implicates monoaminergic, glutamatergic and GABAergic signalling; attenuation of oxidative and inflammatory stress; modulation of stress-response pathways; effects on neurotrophic signalling and neuronal plasticity; and mitochondrial protection. These pathways are compatible with the broader neurobiology of mood and resilience, but most remain mechanistic hypotheses rather than proven mediators in supplemented humans.

This distinction matters. It is reasonable to state that such pathways may help explain observed clinical outcomes. It is not scientifically justified to claim that saffron improves mood because it definitively "raises serotonin", "normalises cortisol" or "increases BDNF" in humans unless those causal steps are demonstrated in the specific intervention and population.

CLINICAL EVIDENCE

05 Sleep and restorative wellbeing

Sleep constitutes the second most commercially attractive evidence territory. A meta-analysis of randomised controlled trials reported improvements in Pittsburgh Sleep Quality Index, Insomnia Severity Index and Restorative Sleep Questionnaire outcomes relative to control. [4]

In a 28-day, three-arm randomised trial of 120 adults with unsatisfactory sleep, participants received placebo, 14 mg or 28 mg of a standardised saffron extract one hour before bed. Saffron improved the primary sleep-quality rating and several insomnia-related measures. Evening melatonin increased relative to placebo, whereas evening cortisol did not show a significant treatment effect. [3]

The field still has limitations: most trials are relatively short, many rely primarily on subjective sleep outcomes, and participants frequently have self-reported poor sleep rather than polysomnographically confirmed insomnia. Accordingly, the defensible proposition is support for sleep quality and restorative sleep, not treatment of insomnia.

POSITIONING LOGIC

06 The mood–sleep biological continuum

Mood, perceived stress and sleep should not be treated as unrelated marketing endpoints. Poor sleep can amplify emotional reactivity and stress susceptibility, while anxiety and depressive symptoms commonly impair sleep initiation, continuity and subjective restorativeness. An ingredient producing modest, reproducible effects across this interconnected network may have greater real-world value than one producing a large change in an isolated biochemical marker.

CROCIVANCE™ POSITIONING ARCHITECTURE

MOOD → STRESS RESILIENCE → RESTORATIVE SLEEP → DAYTIME WELLBEING

EMERGING EVIDENCE

07 Cognition and neuroprotection

The neurocognitive literature is scientifically intriguing but clinically less mature. A systematic review and meta-analysis of four randomised clinical trials in mild cognitive impairment and dementia found favourable effects in some cognitive outcomes, including ADAS-cog and Clinical Dementia Rating Scale measures, while also concluding that the evidence base remained too limited to support clinical recommendation. [5]

Preclinical research has generated hypotheses involving amyloid aggregation, neuroinflammation, oxidative neuronal injury, mitochondrial function and neuronal survival. These findings justify continued investigation of saffron as a neuroprotective nutraceutical candidate, but they do not establish prevention or treatment of Alzheimer's disease.

For CrociVance™, healthy cognitive ageing and cognitive resilience therefore represent a research territory and potential future clinical-development programme, not the first-line commercial claim territory.

BIOAVAILABILITY

08 Pharmacokinetics: crocin is not the whole story

A recurring product-development error is to assume that greater crocin concentration automatically translates into greater human biological activity. Oral pharmacokinetics are more complex. Crocins undergo substantial gastrointestinal transformation, and circulating crocetin becomes an important systemic marker of exposure. [6,7]

In a human pharmacokinetic study using 56 mg and 84 mg doses of a standardised saffron preparation, crocetin appeared in plasma with maximum concentrations approximately 60–90 minutes after intake, supporting rapid transformation of crocin isomers during digestion and absorption. [6]

Consequently, extract development should consider botanical identity, chemical fingerprint, extract matrix, dose, stability and bioaccessibility — not simply "mg saffron" or "% crocins". This directly limits any attempt to declare CrociVance™ clinically equivalent to a third-party extract solely because the nominal daily dose is similar.

MECHANISTIC SUPPORT

09 Oxidative stress and inflammation

Saffron is frequently described as an antioxidant, but this label is too generic to provide meaningful differentiation. An updated meta-analysis of 16 randomised placebo-controlled trials reported reductions in malondialdehyde and total oxidant status together with increases in total antioxidant capacity and glutathione peroxidase. [8]

These biomarker findings support systemic biological activity. Their principal value for CrociVance™ is mechanistic: redox and inflammatory modulation may form part of the biological architecture connecting saffron chemistry to neuronal function, emotional wellbeing and healthy ageing. They should not be converted into broad disease-prevention claims.

SECONDARY TERRITORY

10 Cardiometabolic evidence

Saffron has also been investigated in dyslipidaemia, diabetes, obesity and related cardiometabolic settings. A systematic review and dose-response meta-analysis of 32 studies involving 1,674 participants reported statistically significant improvements in several lipid, glycaemic, inflammatory and anthropometric markers. [9]

Statistical significance, however, must not be confused with clinical importance. A separate meta-analysis of eight randomised trials estimated mean blood-pressure reductions of only 0.65 mmHg systolic and 1.23 mmHg diastolic and explicitly noted that these hypotensive effects were small and might not reach clinical importance. [10]

The appropriate interpretation is therefore that saffron may exert small favourable effects on certain cardiometabolic markers in selected populations. This is a secondary scientific territory, not a basis for positioning CrociVance™ as an antihypertensive, antidiabetic or lipid-lowering ingredient.

LIFE-STAGE WELLBEING

11 Women's health

Clinical work in women suggests that saffron may have relevance during hormonally dynamic life stages, primarily through psychological rather than directly endocrine effects. In a 12-week randomised, double-blind study involving perimenopausal women, 14 mg twice daily of a standardised saffron extract was associated with greater improvement in psychological symptoms, including anxiety and depression-related scores, whereas vasomotor and somatic symptoms did not improve significantly compared with placebo. [11]

That pattern argues against describing saffron as a "hormone balancer". A more defensible future territory would be emotional wellbeing during hormonally challenging life stages, provided that consumer-facing wording complies with the applicable jurisdiction.

EMERGING EVIDENCE

12 Sexual function

A systematic review and meta-analysis of five studies involving 173 participants reported statistically significant positive effects on overall sexual dysfunction and several subdomains. Heterogeneity was moderate, and the total evidence base was small. [12]

This is a plausible secondary application, but not currently a sufficiently mature evidence base to define the core identity of CrociVance™.

RESEARCH TERRITORY

13 Ocular and retinal health

Saffron's carotenoid chemistry has also generated sustained interest in retinal biology. A randomised, double-blind, placebo-controlled crossover study in 100 adults with mild-to-moderate age-related macular degeneration evaluated 20 mg/day of saffron and reported changes in retinal and visual-function outcomes. [13]

The field remains characterised by relatively modest sample sizes and disease-specific heterogeneity. Ocular health is therefore a credible research territory rather than a mature general nutraceutical claim platform.

RISK ASSESSMENT

14 Safety and tolerability

Culinary history should not be used as a shortcut to claim that concentrated saffron extracts are intrinsically risk-free. A 2026 systematic safety review evaluated 102 clinical trials plus one case report involving saffron monopreparations. Nearly 78% of the trials addressed safety; most reported adverse events were minor and self-limiting, with gastrointestinal complaints among the most frequent. [14]

The evidence is generally reassuring at doses used in controlled human studies, but concentrated botanical preparations still require product-specific specifications, contaminant control and appropriate warnings. Particular caution is prudent when considering pregnancy or lactation, relevant medication use, significant medical conditions, unusually high doses or prolonged medicinal use.

QUALITY BY DESIGN

15 Quality, identity and authenticity

Saffron's exceptional value creates a well-recognised authenticity problem. Identity, traceability and adulteration control are therefore not secondary quality topics but core elements of scientific credibility. ISO 3632 provides recognised quality criteria for saffron as a spice, while higher-value nutraceutical extracts require additional chromatographic and contaminant-control architecture.

Recommended CrociVance™ specification architecture

- Botanical identity: Crocus sativus L.; plant part explicitly defined.
- Authenticity controls: botanical, chromatographic and supply-chain verification.
- Crocins: quantitative content and, ideally, chromatographic distribution of relevant isomers.
- Safranal and picrocrocin: defined analytical limits or reporting framework.
- Crocetin: where analytically and biologically relevant.
- Extract ratio, manufacturing process and extraction solvent.
- Residual solvents, microbiology, heavy metals, pesticide residues and relevant mycotoxin risk.
- Moisture / water activity and storage conditions.
- Adulterant screening and validated analytical methods.
- Shelf-life stability, including light, oxygen and temperature sensitivity of carotenoids. [7]

NON-NEGOTIABLE

A numerical standardisation claim should be assigned only after the final commercial extract and analytical method are fixed. A convenient specification invented for marketing purposes would undermine both clinical bridging and regulatory defensibility.

BRAND PLATFORM

16 CrociVance™: the INTABIOTECH scientific proposition

CrociVance™ is conceived as INTABIOTECH's evidence-led Crocus sativus extract platform. The name links the characteristic crocin/crocetin chemistry of saffron with a forward-looking concept of scientific advancement. Its purpose is to differentiate a controlled extract platform from commodity saffron powder without implying that the brand itself already possesses proprietary clinical evidence.

BRAND	**CrociVance™**
DESCRIPTOR	Standardized Saffron Extract by INTABIOTECH
PRIMARY TERRITORY	Mood · Stress resilience · Restorative sleep
RESEARCH TERRITORY	Cognitive resilience / healthy ageing
SCIENTIFIC PRINCIPLE	Analytical reproducibility before claim expansion

PROPOSED SCIENTIFIC POSITIONING

Precision botanical support for mood, resilience and restorative wellbeing.

PRODUCT DEVELOPMENT

17 A rational CrociVance™ development strategy

Several human saffron trials have used daily amounts around 28–30 mg of a particular standardised extract, while other studies have used substantially different quantities. Nominal dose alone does not establish equivalence. The development sequence should therefore be evidence-driven rather than dose-copying.

01	**ANALYTICAL FINGERPRINT**	Lock botanical source, plant part, extraction process, marker profile and validated analytical methods.
02	**STABILITY**	Define marker stability under intended packaging and storage conditions, with particular attention to light, oxygen and temperature.

03	DOSE JUSTIFICATION	Select a daily dose based on composition, bioaccessibility, safety and reasonable comparability with the published literature.
04	CROCiVANCE™ RCT	Conduct a randomised, double-blind, placebo-controlled study using the final proprietary material and pre-specified validated outcomes.
05	MECHANISTIC SUBSTUDY	Where useful, include biomarkers or objective sleep/stress measurements that can strengthen biological plausibility without replacing clinical endpoints.

Why extract-specific trials matter

Several proprietary standardised saffron extracts already possess product-specific clinical studies. Those trials primarily substantiate the tested materials. CrociVance™ should therefore distinguish ingredient-class evidence — showing that Crocus sativus is biologically promising — from product-specific evidence demonstrating outcomes for CrociVance™ itself.

LONG-TERM OBJECTIVE

Literature-backed saffron → analytically defined CrociVance™ → clinically validated CrociVance™.

REGULATORY FRAMEWORK

18 Regulatory reality in the European Union

Scientific publication and legally permitted consumer communication are separate questions. Under Regulation (EC) No 1924/2006, health claims on foods are subject to the European nutrition and health-claims framework. The existence of a positive clinical trial does not itself create permission to reproduce therapeutic or disease-related language on a food supplement label or advertisement. [15]

Botanical claims remain a particularly complex area in the European Union. The EU Register identifies authorised and non-authorised claims, while a number of botanical claims have historically remained under consideration. The exact communication strategy for CrociVance™ must therefore be assessed claim by claim, product by product and market by market. [16]

The Novel Food status of the final extract must similarly be assessed from its botanical material, manufacturing process, extraction conditions, concentration and documented history of consumption rather than inferred solely from the traditional culinary use of saffron. The European Commission's Novel Food Status Catalogue is a useful screening resource but does not replace a full operator assessment. [17]

EVIDENCE SYNTHESIS

19 Evidence hierarchy for saffron health applications

APPLICATION	HUMAN EVIDENCE	INTERPRETATION	PRIORITY
Mood / depressive symptoms	Multiple RCTs + 2026 meta-analysis	Moderate; clinically promising	**VERY HIGH**
Anxiety / psychological stress	Multiple RCTs + meta-analysis	Promising; heterogeneous	**VERY HIGH**
Sleep quality	Several RCTs + meta-analysis	Promising	**HIGH**
Cognition / MCI	Small RCT base + reviews	Promising but insufficient	**RESEARCH**
Oxidative stress	Multiple RCT/meta-analysis biomarker data	Biologically supported	**MECHANISTIC**
Cardiometabolic health	Multiple RCT/meta-analyses	Generally modest / heterogeneous	**SECONDARY**

APPLICATION	HUMAN EVIDENCE	INTERPRETATION	PRIORITY
Women's psychological wellbeing	Limited RCT evidence	Interesting preliminary signal	**SECONDARY**
Sexual function	Small meta-analytic evidence base	Promising but limited	**SECONDARY**
Ocular health	Several small clinical studies	Research territory	**FUTURE**
Disease-treatment claims	Not established for general nutraceutical use	Not justified	**AVOID**

SCIENTIFIC COMMUNICATION

20 The scientific advantage of restraint

One of the strongest potential differentiators for CrociVance™ is not an additional health claim, but disciplined interpretation. The nutraceutical market frequently converts preliminary pharmacology into deterministic statements such as "balances neurotransmitters", "controls cortisol", "prevents cognitive decline" or "natural antidepressant". The current saffron evidence does not justify many of these absolute formulations.

What the evidence does justify is more compelling: a traditional food botanical now has a substantial and growing human clinical literature suggesting measurable effects on several interconnected components of mental wellbeing. That proposition is strong enough without exaggeration.

FINAL ASSESSMENT

21 Conclusion

Saffron has moved beyond its historical identity as a luxury spice. The cumulative evidence increasingly positions Crocus sativus as a legitimate subject of modern nutritional neuroscience. Its pharmacological architecture is complex: crocins undergo substantial gastrointestinal transformation to crocetin; safranal and other constituents may contribute complementary activity; and redox, inflammatory, neurotransmitter and neuroprotective pathways remain biologically plausible components of the observed effects.

Human evidence is strongest for depressive and anxiety symptoms, where the 2026 GRADE-assessed meta-analysis of 34 randomised trials supports a moderate-certainty signal while simultaneously exposing important heterogeneity and differences between self-rated and clinician-rated outcomes. Sleep forms a second promising domain. Cognition, ocular health, cardiometabolic effects, women's wellbeing and sexual function remain scientifically interesting but require varying degrees of additional confirmation.

The strategic conclusion for INTABIOTECH is therefore not that saffron "does everything". It is that a properly characterised saffron extract can occupy a distinctive evidence-led space at the intersection of mood, resilience and restorative wellbeing — provided that analytical reproducibility, clinical bridging and regulatory discipline are treated as core product attributes rather than afterthoughts.

Evidence base cited in this review

1 Mahmoudi R, Mohammadi-Sartang M, Servatyari K, Rafieipour N. Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials. Nutr Neurosci. 2026;29(7):816–837. doi:10.1080/1028415X.2025.2602153. PMID: 41693488. Source

2 Lopresti AL, Smith SJ, Marx W, et al. An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial. J Nutr. 2025;155:2300–2311. doi:10.1016/j.tjnut.2025.05.024. PMID: 40414301. Source

3 Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Med. 2021;86:7–18. doi:10.1016/j.sleep.2021.08.001. PMID: 34438361. Source

4 Lian J, Zhong Y, Li H, et al. Effects of saffron supplementation on improving sleep quality: a meta-analysis of randomized controlled trials. Sleep Med. 2022;92:24–33. doi:10.1016/j.sleep.2022.03.001. PMID: 35325766. Source

5 Ayati Z, Yang G, Ayati MH, Emami SA, Chang D. Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials. BMC Complement Med Ther. 2020;20:333. doi:10.1186/s12906-020-03102-3. PMID: 33167948. Source

6 Almodóvar P, Briskey D, Rao A, Prodanov M, Inarejos-García AM. Bioaccessibility and Pharmacokinetics of a Commercial Saffron (Crocus sativus L.) Extract. Evid Based Complement Alternat Med. 2020;2020:1575730. doi:10.1155/2020/1575730. PMID: 32089715. Source

7 Hosseini A, Razavi BM, Hosseinzadeh H. Pharmacokinetic Properties of Saffron and its Active Components. Eur J Drug Metab Pharmacokinet. 2018;43(4):383–390. doi:10.1007/s13318-017-0449-3. PMID: 29134501. Source

8 Abedi A, Ghobadi H, Sharghi A, Iranpour S, Fazlzadeh M, Aslani MR. Effect of saffron supplementation on oxidative stress markers: an updated systematic review and meta-analysis of randomized placebo-controlled trials. Front Med (Lausanne). 2023;10:1071514. doi:10.3389/fmed.2023.1071514. PMID: 36817799. Source

9 Zamani M, Zarei M, Nikbaf-Shandiz M, et al. The effects of saffron supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis. Front Nutr. 2022;9:1055517. doi:10.3389/fnut.2022.1055517. PMID: 36570145. Source

10 Setayesh L, Ashtary-Larky D, Clark CCT, et al. The Effect of Saffron Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrients. 2021;13(8):2736. doi:10.3390/nu13082736. PMID: 34444896. Source

11 Lopresti AL, Smith SJ. The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study. J Menopausal Med. 2021;27(2):66–78. doi:10.6118/jmm.21002. PMID: 34463070. Source

12 Ranjbar H, Ashrafizaveh A. Effects of saffron (Crocus sativus) on sexual dysfunction among men and women: A systematic review and meta-analysis. Avicenna J Phytomed. 2019;9(5):419–427. PMID: 31516855. Source

13 Broadhead GK, Grigg JR, McCluskey P, et al. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Graefes Arch Clin Exp Ophthalmol. 2019;257(1):31–40. doi:10.1007/s00417-018-4163-x. PMID: 30343354. Source

14 Hasheminasab FS, Hajimonfarednejad M, Najibi SM, Hashempur MH. Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence. Health Sci Rep. 2026;9(5):e72212. doi:10.1002/hsr2.72212. PMID: 42057871. Source

15 European Parliament and Council. Regulation (EC) No 1924/2006 on nutrition and health claims made on foods. Source

16 European Commission. EU Register of nutrition and health claims made on foods; botanical claims framework. Accessed September 2026. Source

17 European Commission. Novel Food Status Catalogue. Accessed September 2026. Source

18 ISO 3632 (series). Saffron (Crocus sativus L.) — specifications and test methods. International Organization for Standardization. Source

SCIENTIFIC & REGULATORY NOTICE

Responsible use of this document

This document is intended for scientific, technical and B2B informational purposes. It reviews published research on saffron and selected saffron preparations and proposes a development framework for ***CrociVance™****. It does not constitute medical advice and does not establish that* ***CrociVance™*** *prevents, diagnoses, treats or cures any disease.*

References to clinical studies performed with third-party proprietary saffron preparations are included to describe the scientific literature on the ingredient category. They must not be interpreted as evidence of clinical equivalence, bioequivalence or product-specific efficacy for ***CrociVance™*** *unless such equivalence is demonstrated by appropriate analytical, pharmacokinetic and/or clinical bridging.*

CrociVance™ *is a proposed proprietary commercial designation of INTABIOTECH. Final trademark clearance, registration, specification, regulatory status, permitted claims, dosage and labelling must be confirmed before commercial launch in each relevant jurisdiction, as it may, an sure differ.*

INTABIOTECH

Science · Technology · Evidence-led Ingredient Innovation

Intabiotech Publishing Service

Paterna, Valencia, Spain